Skip to content

Ketamine: all studies

Page 399 of 448: studies 3,981 to 3,990 of 4,475, newest first. Back to the ketamine overview

Research

Interventional Mental Health: A Transdisciplinary Approach to Novel Psychiatric Care Delivery.

Cureus August 1, 2023 Jonathann Kuo, Tabitha Block, Megan Nicklay et al. 2 citations

Mental health disorders are among the most common health conditions in the United States. Traditional clinical treatments rely on psychiatric counseling and, in many cases, prescription medications. We propose an innovative model, Interventional Mental Health, which employs a combination of modalities through a multifaceted approach to treat conditions that have exhibited limited responsiveness...

DOI: 10.7759/cureus.43533 (opens in new tab) Full text (opens in new tab) Treatment-resistant depression Autonomic dysregulation Iv ketamine infusion Treatment of depression

Festivals following the easing of COVID-19 restrictions: Prevalence of new psychoactive substances and illicit drugs.

Environment international August 1, 2023 Nikolaos Rousis, Richard Bade, Iván Romero-Sánchez et al. 33 citations

The market for illicit drugs and new psychoactive substances (NPS) has grown significantly and people attending festivals have been identified as being at high risk (high extent and frequency of substance use). Traditional public health surveillance data sources have limitations (high costs, long implementation times, and ethical issues) and wastewater-based epidemiology (WBE) can...

DOI: 10.1016/j.envint.2023.108075 (opens in new tab) Full text (opens in new tab) 2f-deschloroketamine 2f-dck 3-chloromethcathinone 3-cmc N,N-Dimethylpentylone Substance abuse +2

Psychedelics and Related Pharmacotherapies as Integrative Medicine for Older Adults in Palliative Care.

Clinics in geriatric medicine August 1, 2023 Kabir Nigam, Kimberly A Curseen, Yvan Beaussant 3 citations

Psychological distress at the end of life is a common experience that lacks effective treatments. This is in part due to the multidimensional nature of psychological distress at the end of life, encompassing an interplay between psychosocial and existential distress as well as physical symptom burden. Research shows that psychedelic-assisted therapy is an effective treatment of end of life...

Psychedelic medicines for end-of-life care: Pipeline clinical trial review 2022.

Palliative & Supportive Care August 1, 2023 Xuepeng Jing, Nicholas Hoeh, David B Menkes 18 citations

People with terminal illnesses often experience psychological distress and associated disability. Recent clinical trial evidence has stimulated interest in the therapeutic use of psychedelics at end of life. Much uncertainty remains, however, mainly due to methodological difficulties that beset existing trials. We conducted a scoping review of pipeline clinical trials of psychedelic treatment...

THE CONNECTION BETWEEN THE INDIVIDUAL SUBJECTIVE WELL-BEING AND THE MYSTICAL EXPERIENCE PRODUCED BY THE USE OF PSYCHEDELICS

PSYCHOLOGICAL JOURNAL July 31, 2023 Tetiana Kudrina, Kozlovska Anna

Respondents with experience in the use of psychedelics (psilocybin, LSD, ketamine, MDMA, etc.) participated in the study. Based on the subjective assessment of the level of awareness in the topic of psychedelics, it was found that 49% of respondents have a high level, 47% have an average level, and 4% have a low level of awareness in the topic. Most of the study participants were in Ukraine...

Dissociative identity precipitated by emergence from general anesthesia: A case report and analytical framework

Psychiatry Research Case Reports July 26, 2023 Gregory W. Kirschen, Mary E. Shorey, Joan C. Han et al.

Background: Dissociative identity disorder (DID) is a complex and controversial psychiatric condition in which one person maintains at least two separate and distinct personalities. Patients with DID often report a history of childhood abuse and may have other comorbid psychiatric conditions. Psychosocial stressors may be triggers for DID inception or recurrence. While anesthetic agents, in...

DOI: 10.1016/j.psycr.2023.100152 (opens in new tab) Dissociative identity disorder Dissociative disorders Psychosocial Multiple personality disorder +10

5-HT2AR and NMDAR psychedelics induce similar hyper-synchronous states in the rat cognitive-limbic cortex-basal ganglia system.

Communications Biology July 26, 2023 Ivani Brys, Sebastian A Barrientos, Jon Ezra Ward et al. 33 citations

The profound changes in perception and cognition induced by psychedelic drugs are thought to act on several levels, including increased glutamatergic activity, altered functional connectivity and an aberrant increase in high-frequency oscillations. To bridge these different levels of observation, we have here performed large-scale multi-structure recordings in freely behaving rats treated with...

DOI: 10.1038/s42003-023-05093-6 (opens in new tab) Full text (opens in new tab) Psychedelics Brain waves Consciousness Pharmacology

Psychedelic medicines

Australian Journal of Chemistry July 16, 2023 Matthew Piggott, Peter J. Duggan 1 citation

The recent heightened public enthusiasm for the potential therapeutic benefits of psychedelics, especially for treatment-resistant mental health conditions, has resulted in a renewed interest in the underlying science that governs their properties and pharmacology.The science of psychedelics is an intriguing, multi-disciplinary field and encompasses many known psychedelic substances, including...

Outcomes of usage of psychedelics by people reporting an eating disorder in clinical and non-clinical settings: a scoping review

Advances in Mental Health July 13, 2023 Jorge Valdiviezo‐oña, Lizbeth Toscano-Molina, Juan Fernando Chávez et al. 4 citations

Objective To map the studies reporting the use of psychedelics in clinical and non-clinical settings by people reporting an eating disorder (ED) and their outcomes.Method To be included, peer-reviewed articles had to be written in English or Spanish and had to address the usage of psychedelics by people reporting an ED. Searches were conducted on PubMed, Scopus, and Web of Science. Data on key...

The Role of Glutamate Underlying Treatment-resistant Depression

Clinical Psychopharmacology and Neuroscience July 10, 2023 Jeongseop Kim, Tae-Eun Kim, Seung Hwan Lee et al. 29 citations

The monoamine hypothesis has significantly improved our understanding of mood disorders and their treatment by linking monoaminergic abnormalities to the pathophysiology of mood disorders. Even 50 years after the monoamine hypothesis was established, some patients do not respond to treatments for depression, including selective serotonin reuptake drugs. Accumulating evidence shows that patients...